Cancer Therapy News and Research

RSS

Compound derived from cottonseed oil could help improve the effectiveness of chemotherapy at treating head and neck cancer

The findings, which will be presented Tuesday, April 19, at the American Association for Cancer Research annual meeting, could lead to a treatment that provides an effective option to surgically removing the cancer, helping patients preserve vital organs involved in speech and swallowing.

19 Apr 2005

Scientists identifiy protein that seems to control the malignant features of brain tumor cells

Scientists from Wake Forest University School of Medicine have identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. The research is reported in the current issue of Molecular Cancer Research.

13 Apr 2005

Race influences how we cope with cancer

White patients cope better with the pressure of cancer than their British Asian counterparts according to research published on-line in the British Journal of Cancer.

12 Apr 2005

Genetic testing could bolster radiotherapy's effectiveness against cancer

Obtaining a genetic picture of how a tumor will react to the many treatment techniques available could help doctors prescribe therapies customized for individual cancer patients' needs, suggests a Purdue University research team.

5 Apr 2005

Important trial in the fight against lung cancer

Two University of Kentucky researchers continue their work with a vaccine to prevent lung cancer recurrences in patients following primary treatment of the disease.

5 Apr 2005

Tarvacin shows significant anti-viral activity

Peregrine Pharmaceuticals today announced that there will be two presentations, April 4 and 6, at the American Association of Immunologists (AAI) annual meeting in San Diego, California, indicating the anti-viral potential of its Tarvacin antibody. Dr. Melina Soares of The University of Texas Southwestern Medical Center at Dallas will present pre-clinical data titled "Targeting inside-out phospholipids on viruses in a guinea pig model of Lassa fever."

4 Apr 2005

Men who are treated for prostate cancer with radiation may have almost doubled their risk of developing rectal cancer

A study in the American Gastroenterological Association (AGA) journal Gastroenterology has found that men who are treated for prostate cancer with radiation may have almost doubled their risk of developing rectal cancer when compared to men who opted to have surgery.

4 Apr 2005

Radiation for prostate cancer doubles the risk of developing rectal cancer

Men who undergo radiation for prostate cancer have nearly double the risk of developing rectal cancer when compared to men who opt to have surgery to treat prostate cancer, according to a study published today in the American Gastroenterological Association (AGA) journal Gastroenterology.

3 Apr 2005

Construction will enable pSivida to increase BrachySil production

Global nanotechnology company pSivida Limited has announced that it's UK manufacturing partner, Atomising Systems Ltd ("ASL"), has reached a key milestone in the manufacture of BrachySil, its lead product, by completing construction of a state of the art dedicated cleanroom facility to GMP specifications at its Sheffield plant in the United Kingdom. ASL is a world leader in high temperature atomising technology.

30 Mar 2005

First North American trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer

Today, a new clinical trial evaluating a novel approach to breast cancer prevention launched in the United States and Canada. Called the ExCel research study, this is the first North American clinical trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer.

30 Mar 2005

Diffusion MRI gives early indication if brain cancer therapy is effective

A special type of MRI scan that measures the flow of water molecules through the brain can help doctors determine early in the course of brain cancer regimen if a patient's tumor will shrink, a new study shows.

28 Mar 2005

Smart nanocarrier technology will cancer treatment

A ‘smart’ nanocarrier technology developed by a team of researchers at the Institute of Bioengineering and Nanotechnology (IBN) is set to vastly improve the way cancer patients are treated.

22 Mar 2005

Most cancer patients can be very hopeful for a good outcome and a continued ability to work

Only one of five cancer survivors surveyed in a Penn State study were disabled or out of work four years after treatment, but a minority suffered lasting effects that prevented them from working.

22 Mar 2005

pSivida intensifies research activities

Following extremely encouraging Phase IIa clinical trial results showing successful tumor regression and safety in man, nanotechnology pioneer pSivida Limited is intensifying development of its fully patented invention of nanostructured bioactive, biodegradable and biocompatible silicon (BioSilicon™) for multiple potential healthcare applications.

21 Mar 2005

Cancer survival comes at its own price

Patients who hear the dreaded words "you have cancer" invariably look forward to the day the doctor tells them "you're cured." But University of Florida researchers say survival often comes at its own price -- the mind may need mending even after the body heals.

16 Mar 2005

Drug combo gives lung cancer patients longer life

Preliminary results from a large randomized clinical trial, sponsored by the National Cancer Institute (NCI), by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., have shown that patients with previously untreated advanced non-squamous non-small cell lung cancer who received bevacizumab (Avastin) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Novel Australian anti-cancer therapy has begun safety testing in human subjects

An international medical conference here heard that an Australian developed anti-cancer therapy based on the use of a common cold virus to control cancer cell growth has begun safety testing in human subjects.

15 Mar 2005

Good results in new lung cancer treatment

Interim analysis of a Phase III study of Avastin (bevacizumab) with paclitaxel and carboplatin chemotherapies in first-line non-squamous, non-small cell lung cancer (NSCLC) met its primary goal of improving overall survival, or a reduction in the risk of death, compared to chemotherapy alone.

15 Mar 2005

New cancer drug looks promising

Dr. E. Premkumar Reddy from Temple University School of Medicine and colleagues, in a study examining the effects of Plk1 inhibitor ON01910 on tumor growth in several animal models have found that a small molecule inhibitor of polo-like kinase1 (Plk1) could lead to a new avenue for targeted cancer therapy.

14 Mar 2005